Characterization of the brain network architecture and its alterations in pathologies are essential for a better understanding of mechanisms of action in health and disease and paves the way for the development of targeted therapeutic strategies. In the field of demyelinating disorders, thyromimetic treatment provides a promising remyelinating strategy inducing oligodendrogenesis in vitro. We tested the potential of sobetirome (GC-1), a thyroid hormone analogue, to induce remyelination in vivo in the cuprizone demyelinated mouse model and we investigated its action on the resting state (rsfMRI) mouse brain functional connectivity.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords